News
06-08-2010, 03:18 AM
Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 68 patients were enrolled with platinum-resistant disease, half of whom were platinum refractory. All 68 patients were evaluable for the primary endpoint of objective response rate using Gynecologic Cancer InterGroup criteria, which is a combination of response by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125) criteria.
More... (http://www.news-medical.net/news/20100608/Phase-2-Study-NKTR-102-holds-great-therapeutic-potential-for-women-with-platinum-resistantrefractory-ovarian-cancer.aspx)
More... (http://www.news-medical.net/news/20100608/Phase-2-Study-NKTR-102-holds-great-therapeutic-potential-for-women-with-platinum-resistantrefractory-ovarian-cancer.aspx)